Atara Biotherapeutics - ATRA Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares.
View ATRA analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 1 year price objectives for Atara Biotherapeutics' stock. Their ATRA share price forecasts range from $3.00 to $50.00. On average, they predict the company's share price to reach $18.71 in the next twelve months. This suggests a possible upside of 355.3% from the stock's current price.
View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts.

Atara Biotherapeutics' stock was trading at $15.76 at the beginning of the year. Since then, ATRA stock has decreased by 73.9% and is now trading at $4.11.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ATRA earnings forecast.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its earnings results on Monday, August, 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.60. The biotechnology company earned $51.58 million during the quarter, compared to the consensus estimate of $8.84 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 111.20% and a negative net margin of 344.87%. During the same quarter in the previous year, the company earned ($0.91) earnings per share.

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRA stock can currently be purchased for approximately $4.11.

Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $387.83 million and generates $20.34 million in revenue each year. The biotechnology company earns $-340,140,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

The company employs 578 workers across the globe.

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (650) 278-8930 or via email at ehyllengren@atarabio.com.